GeneDx Holdings Corp. (NASDAQ:WGS) is a company based in Gaithersburg, Maryland, operating within the Zacks Medical Services industry. It focuses on providing genetic testing services, which are crucial for diagnosing and managing various health conditions. The company competes with other firms in the medical services sector, striving to maintain its position through consistent financial performance and strategic initiatives.
On February 23, 2026, Jefferies adjusted its price target for WGS to $150, down from $180. At the time, WGS was trading at $87.08, indicating a significant gap of approximately 72.26% from the new target. This adjustment comes amid GeneDx's strong financial performance, as highlighted by Seeking Alpha during its Q4 2025 earnings call.
GeneDx reported quarterly earnings of $0.14 per share, surpassing the Zacks Consensus Estimate of $0.11. This represents a 27.27% earnings surprise, showcasing the company's ability to exceed expectations. In the previous quarter, GeneDx also outperformed with earnings of $0.49 per share against an anticipated $0.28, resulting in a 75% surprise.
The company reported revenues of $121 million for Q4 2025, exceeding the Zacks Consensus Estimate by 1.5%. This is a significant increase from the $95.64 million recorded in the same quarter the previous year. GeneDx has consistently surpassed consensus revenue estimates over the past four quarters, highlighting its robust financial health.
Currently, WGS is priced at $87.08, reflecting a 6.12% increase. The stock has fluctuated between $79.01 and $87.93 today, with a market capitalization of approximately $2.52 billion. Over the past year, WGS has seen a high of $170.87 and a low of $55.17, indicating its volatile nature in the market.
